Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
نویسندگان
چکیده
Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.
منابع مشابه
Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
Interstitial lung disease (ILD) is a leading cause of death in systemic sclerosis (SSc). Two randomized controlled trials recently demonstrated the modest effects of cyclophosphamide on lung physiology (forced vital capacity) and extrapulmonary outcomes (dyspnea, function, quality of life, and skin thickening). Recommendations can now be made about the short-term management for SSc-ILD. However...
متن کاملSystemic sclerosis - associated interstitial lung disease – proposed recommendations for future randomised clinical trials
1Division of Rheumatology, 2Biomathematics, 3Pulmonary and Critical Care, Department of Medicine, and 4Department of Radiology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 5Department of Medicine, National Jewish Health, Denver, CO, USA; 6Division of Rheumatology, University of Connecticut Health Center, Farmington, CT, USA; 7Division of Rheumatology, Medical University of So...
متن کاملEffects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
INTRODUCTION The purpose of the present study was to systematically review the effect of cyclophosphamide treatment on pulmonary function in patients with systemic sclerosis and interstitial lung disease. METHODS The primary outcomes were the mean change in forced vital capacity and in diffusing capacity for carbon monoxide after 12 months of therapy in patients treated with cyclophosphamide....
متن کاملInterstitial lung disease in connective tissue disorders.
Some of the most pressing challenges associated with interstitial lung disease (ILD) are how best to define, diagnose, and treat connective tissue disease-associated ILD (CTD-ILD)--disorders with potentially substantial morbidity and mortality. In this focused review, we address aspects of prognosis for CTD-ILD and what indices might predict outcome, together with lessons that can be learnt fro...
متن کاملRecent advances in the diagnosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma): a review.
Interstitial lung disease (ILD) in systemic sclerosis (scleroderma) is a rare and potentially lethal and devastating autoimmune disease, and yet the cause of it remains poorly understood. It is associated with tissue fibrosis not only in the lungs, but also other organs like the heart and kidneys. Although ILD can manifest itself in various disease presentations, ILD in systemic sclerosis is pa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical and experimental rheumatology
دوره 28 2 Suppl 58 شماره
صفحات -
تاریخ انتشار 2010